AlzeCure Pharma (OM:ALZCUR) - Aandelenkoers, Nieuws & Analyse

ALZCUR Overzicht aandelen

ALZCUR fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 39.45% per jaar groeien

De winst is de afgelopen 5 jaar met 9.7% per jaar gegroeid

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( SEK0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 32.5% per jaar dalen.

Heeft geen betekenisvolle marktkapitalisatie ( SEK95M )

Volatiele aandelenkoers in de afgelopen 3 maanden

+ 2 meer risico's

AlzeCure Pharma AB (publ) Concurrenten

PEPTONIC medical

NGM:PMED

SEK 92.1m

Lipidor

OM:LIPI

SEK 108.2m

AcuCort

NGM:ACUC

SEK 113.0m

CS Medica

NGM:CSMED

DKK 60.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor AlzeCure Pharma
Historische aandelenkoersen
Huidige aandelenkoers	SEK 1.08
52 Week Hoogtepunt	SEK 4.00
52 Week Laag	SEK 0.94
Bèta	0.29
11 maand verandering	-39.94%
3 maanden verandering	-44.59%
1 Jaar Verandering	-72.58%
33 jaar verandering	-83.41%
5 jaar verandering	-75.76%
Verandering sinds IPO	-90.23%

Recent nieuws en updates

Recent updates

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

Feb 03

We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Dec 13

Rendement voor aandeelhouders

	ALZCUR	SE Pharmaceuticals	SE Markt
7D	-5.7%	2.4%	0.5%
1Y	-72.6%	7.9%	12.3%

Rendement versus industrie: ALZCUR presteerde slechter dan de Swedish Pharmaceuticals -sector, die het afgelopen jaar een rendement van 7.9 % opleverde.

Rendement versus markt: ALZCUR presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 12.3 % opleverde.

Prijsvolatiliteit

Is ALZCUR's price volatile compared to industry and market?
ALZCUR volatility
ALZCUR Average Weekly Movement	8.5%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.4%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: De aandelenkoers van ALZCUR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van ALZCUR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Swedish.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2012	11	Martin Jönsson	www.alzecurepharma.se

AlzeCure Pharma AB (publ), een farmaceutisch bedrijf, ontwikkelt geneesmiddelentherapieën voor de behandeling van ernstige ziekten en aandoeningen die het centrale zenuwstelsel aantasten. Het bedrijf is betrokken bij de ontwikkeling van kandidaat-geneesmiddelen gebaseerd op de onderzoeksplatformen NeuroRestore, Alzstatin en Painless. De productpijplijn omvat ACD856 voor de behandeling van de ziekte van Alzheimer, slaapstoornissen, depressie, traumatisch hersenletsel en de ziekte van Parkinson, die zich in fase I van het klinisch onderzoek bevindt; ACD857, ACD679 en ACD680 die zich in preklinisch onderzoek bevinden voor de behandeling van de ziekte van Alzheimer; ACD440, een TRPV1-antagonist die fase I van de klinische studie voor indicaties van neuropathische pijn heeft voltooid; en ACD137, een negatieve allosterische modulator (NAM) van TrkA-receptoren voor indicaties van osteoartritische pijn.

AlzeCure Pharma AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van AlzeCure Pharma zich tot de beurswaarde?
ALZCUR fundamentele statistieken
Marktkapitalisatie	SEK 94.92m
Inkomsten(TTM)	-SEK 35.66m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-2.7x

Koers/Winstverhouding

Is ALZCUR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALZCUR resultatenrekening (TTM)
Inkomsten	SEK 0
Kosten van inkomsten	SEK 0
Brutowinst	SEK 0
Overige uitgaven	SEK 35.66m
Inkomsten	-SEK 35.66m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 27, 2025

Winst per aandeel (EPS)	-0.40
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ALZCUR op de lange termijn?

Bekijk historische prestaties en vergelijking

ALZCUR Overzicht aandelen

Beloningen

Risicoanalyse

AlzeCure Pharma AB (publ) Concurrenten

NGM:PMED

SEK 92.1m

OM:LIPI

SEK 108.2m

NGM:ACUC

SEK 113.0m

NGM:CSMED

DKK 60.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Revenue and earnings growth

New minor risk - Share price stability

AlzeCure Pharma AB (publ) Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

AlzeCure Pharma AB (publ) to Report Q2, 2025 Results on Aug 26, 2025

AlzeCure Pharma AB (publ) Announces an Abstract with Preclinical Data on NeuroRestore ACD856 Demonstrating Its Anti-In-In-In-Class Drug Candidate for Alzheimer's Disease

AlzeCure Pharma AB (publ) Announces New Results from Alzecure's Pain Project TrkA- NAM Presented At the Pain Conference IASP 2024

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Share price stability

AlzeCure Pharma AB (publ) Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

AlzeCure Pharma AB (publ) to Report Q2, 2025 Results on Aug 26, 2025

AlzeCure Pharma AB (publ) Announces an Abstract with Preclinical Data on NeuroRestore ACD856 Demonstrating Its Anti-In-In-In-Class Drug Candidate for Alzheimer's Disease

AlzeCure Pharma AB (publ) Announces New Results from Alzecure's Pain Project TrkA- NAM Presented At the Pain Conference IASP 2024

New minor risk - Shareholder dilution

Alzecure Pharma AB (Publ) Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

Price target decreased by 10% to kr13.00

AlzeCure Pharma AB (publ) Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024

New major risk - Market cap size

AlzeCure Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 52.77396 million.

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference

AlzeCure Pharma AB (publ) Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's

New minor risk - Share price stability

AlzeCure Pharma AB (publ) Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

AlzeCure Pharma AB (publ) Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain

We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth

AlzeCure Pharma AB (publ) Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD

AlzeCure Pharma AB (publ) Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856

Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference

AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference

AlzeCure Pharma AB (publ) Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference

AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024

New minor risk - Financial position

AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024

AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's

Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth

AlzeCure Pharma AB (Publ) Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders

Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Forecast to breakeven in 2025

Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440

AlzeCure Pharma AB (publ) Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

Alzecure Pharma AB (Publ) Gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's

AlzeCure Pharma AB (publ) Gets Late-Breaking Abstract on New Data with Alzheimer Project

Alzecure Pharma AB (Publ) Announces New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented At Alzheimer's Conference CTAD

Alzheimer Announces New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856

Price target decreased to kr12.00

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856

Price target decreased to kr12.00

Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?

AlzeCure Pharma AB (publ) Announces New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856

AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022

AlzeCure's Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial

AlzeCure Pharma AB (publ), Annual General Meeting, May 17, 2023

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

AlzeCure Pharma AB Gets Abstract on New Clinical Study Data with NeuroRestore Accepted At the Alzheimer's Conference Aaic

AlzeCure Pharma AB (Publ) Announces Update on Clinical Phase I Study

AlzeCure Pharma AB (publ) Announces First Patient Included in its Phase II Clinical Trial in Neuropathic Pain with Non-Opioid ACD440

Alzecure Pharma AB (Publ)'s Abstract on Pain Project TrkA-NAM Accepted for Presentation At IASP 2022

AlzeCure Pharma AB (publ) Gets Approval to Start Phase II Clinical Trial with Non-Opioid Pain Project ACD440

AlzeCure Pharma AB (publ) Publishes New Data on Alzstatin from Alzheimer Conference

AlzeCure Publishes New Data on NeuroRestore and Acd856 from Alzheimer's Conference

Chief Executive Officer recently bought kr163k worth of stock

Chief Executive Officer recently bought kr163k worth of stock

Chief Financial Officer recently bought kr120k worth of stock